Chemistry:Aloxiprin
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C18H15AlO9 |
| Molar mass | 402.288 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Aloxiprin (or aluminium acetylsalicylate) is a medical drug used for the treatment of pain and inflammation associated with muscular skeletal and joint disorders.[1] It is used for its properties as an anti-inflammatory, antipyretic and analgesic drug.[1] It is a chemical compound of aluminium hydroxide and aspirin.[2][3]
Alternative names and combinations
- Palaprin Forte.[4]
- Askit Powders - A powder combination of aspirin, aloxiprin and caffeine.[5]
Contraindications
- People with allergies to salicylates.
- People with gastrointestinal ulcers.
- People with liver or kidney damage.
- Pregnant women in the 3rd trimester.
- Women who are breastfeeding.
- Use with other salicylates.
- Use with NSAIDs.
References
- ↑ 1.0 1.1 MIMS. "Aloxiprin". MIMS. http://www.mimsonline.com/USA/drug/info/aloxiprin?type=brief&h=nonsteroidal,anti,inflammatory,drugs,nsaids.
- ↑ Encarta. "Aloxiprin". Encarta. http://uk.encarta.msn.com/dictionary_1481579253_1861822000/prevpage.html.[yes|permanent dead link|dead link}}]
- ↑ "In vitro and in vivo properties of aloxiprin: a new aluminium derivative of acetylsalicylic acid". J. Pharm. Pharmacol. 15: 56–62. 1963. doi:10.1111/j.2042-7158.1963.tb12743.x. PMID 14024235.
- ↑ Geller J (1968). "A comparative trial of aloxiprin ('Palaprin Forte') and phenylbutazone ('Butazolidin')". The British Journal of Clinical Practice 22 (9): 392–4. PMID 4876729.
- ↑ Net Doctor UK. "Askit Powders". Treatments for joint, muscle and bone conditions. http://www.netdoctor.co.uk/medicines/100000180.html.
External links
- CTD's Aloxiprin page[yes|permanent dead link|dead link}}] from the Comparative Toxicogenomics Database
 |  |
